New approaches to the treatment of breast cancer
Vol. 70 No. 1 (2024), Articles
Vol. 70 No. 1 (2024)

New approaches to the treatment of breast cancer

Articles
https://doi.org/10.37469/0507-3758-2013-59-3-288-291
Published 15.12.2013

Abstract

За два прошедших года после конференции в Сан-Галлене (2011 ) наблюдается существенный прогресс многих аспектов лечения рака молочной железы (РМЖ). Геномный атлас, вырисовывая гетерогенность РМЖ, свидетельствует о том, что геномные исследования помогут в планировании лечения. Накапливается все больше данных о целесообразности полной подмышечной диссек-ции, оптимальной продолжительности терапии трастузумабом, гормонотерапии.
https://doi.org/10.37469/0507-3758-2013-59-3-288-291
##article.numberofdownloads## 49
##article.numberofviews## 173
PDF (Русский)

References

Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Нео-адъювантное и адъювантное лечение рака молочной железы. М. «Мединформ агенство». — 2008. — 288 с.

Burstein H.J. Triple-negative breast cancer: Is there an optimal adjuvant treatment? // The Breast.—2013.-Vol. 22 (Supp 1). — p. S16 (Abstr. SP9.02).

Cheang MCU, Chia SK, Voduc D et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer // J Natl Cancer Inst.—2009. — Vol. 101. — p. 736-750.

Davidson NE. Optimal systemic therapy for premenopausal women with hormone receptor — positive breast cancer // The Breast.—2013. — Vol. 22 (Supp 1). — p. S18 (Abstr. SP10.02).

Davies С, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. // Lancet 2013. — Vol. 81. — p. 805-816.

Galimberti V. How to handle positive sentinel nodes? // The Breast 2013. Vol. 22 (Supp 1). — p.S11 (Abstr. SP7.01).

Galimberti V, Cole BF, Zurrida S et at. Axillary dissection versus no axillary dissection in patients with sentinel-node mcrometastases (IBCSG 23-01): a phase 3 randomised controlled trial // Lancet Oncol.—2013. — Vol.38. — p. 1020-1045.

Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in with invasive breast cancer and sentinel node metastasis // JAMA. — 2011. — Vol. 305. — p. 75.

Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes — dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 // Ann Oncol. — 2011. — Vol. 22. -p. 1736-1747.

Goldhirsch A, Piccart M, Procter М et al. LBA6-PR — HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Presented at: 37th European Society for Medical Oncology 2012 Congress; September 28-0ctober 2, 2012; Vienna, Austria. (Abstract LBA 6).

Goldhirsch A. Personalized adjuvant therapies: Lessons from the past // The Breast.— 2013. — Vol. 22 (Supp 1). — p. S1 (Abstr. SP0.01).

Goss РЕ, Ingle JN, Martino S et at. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole // Ann Oncol.— 2013. — Vol. 24. — p. 355-361.

Harris JR. Hypofractionation in the era of modulated radiotherapy (RT): Its use in whole breast irradiation (WBI) // The Breast.—2013. — Vol. 22 (Supp 1). — p. S14 (Abstr. SP8.02).

Orecchia R. Partial Breast irradiation: targeting volume or breast molecular subtypes? // The Breast 2013. — Vol. 22 (Supp 1). — p. S14 (Abstr. SP8.01).

Piccart M. Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies // The Breast.—2013. — Vol. 22 (Supp 1). — p. S16 (Abstr. SP9.04).

Pivot X, Romieu G, Bonnefoi H et al. PHARE trial results comparing 6 to 12 month of trastuzumab in adjuvant early breast cancer // Ann Oncol.— 2012. — Vol. 23. — P. 461467.

Prat A, Cheang MC, Martin М et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminat a breast cancer // J Clin Oncol.—2013. — Vol. 31. — p. 203-209.

Rutgers E. Who should NOT have breast conservation? // The Breast 2013. — Vol. 22 (Supp 1). — p. S13 (Abstr. S Р 7.04).

Sedlmayer F. Partial breast re-irradiation for local recurrenсе of breast carcinoma: Benefit and potential long term side effects // The Breast.— 2013. — Vol. — 22. (Supp 1). — p. S15 (Abstr. SP8.04).

Smith L. Follow up tests to detect recurrent disease: patient reassurance or medical need? // The Breast.— 2013. — Vol. 22 (Supp 1). — p. S17 (Abstr. SP9.05).

Whelan TJ, Pignol JP, Levine MN et al. Long-term results of hypofractionated radiation therapy for breast cancel // N Engl J Med. — 2010. — Vol. 362. — p. 513-520.

Wood WC. Additional Resection or No Resection? // The Breast.— 2013. — Vol. 22 (Supp 1). — p. S13 (Abstr. SP7.05).

Yarnold JR. The UK START (standardisation of breast radiotherapy) Trials: 10-year follow-up results. Presented at the 35th San Antonio Breast Cancer Symposium, December 4 — 8, 2012 (Abstr. S4-1).

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...